TORONTO, April 30, 2021
Winterlight Labs is proud to be a participant in the Digital Medicine Society's latest "Tour of Duty" to drive adoption of The Digital Clinical Measures Playbook. The Playbook is the industry-wide essential guide for developing and deploying digital clinical measures to advance patient care, clinical research, and public health. Winterlight Labs joined other leading organizations in life sciences, healthcare, technology and regulatory affairs to develop over 100 new resources to advance digital clinical measures across healthcare.
The Playbook’s new suite of resources were designed to provide relevant, accessible, and action oriented resources on key topics relating to how to develop and integrate digital tools into clinical research and practice. These resources, developed through pre-competitive collaboration, will help members in the health, technology and research sectors better navigate the digital health landscape and standardize how novel digital tools are used and validated.
Through this partnership, Winterlight Labs collaborated with leaders in the field to help advance the safe, effective, ethical, and equitable use of digital clinical measures to improve lives. The over 100 fit-for-purpose resources are available at playbook.dimesociety.org to enable everyone across the field to make better decisions faster.
Winterlight Labs is commercializing a proprietary language-based diagnostic system that analyzes natural speech to detect and monitor dementia, Alzheimer’s, aphasia, and various other cognitive conditions. Winterlight's scalable platform uses short recorded speech samples to analyze hundreds of linguistic cues, and can detect dementia and other conditions with a high level of accuracy. This is a major improvement over current pencil-and-paper tests which are time-consuming, costly, and difficult to administer. The platform has applications in drug trials, long-term and primary care, and speech-language pathology.
Since its founding, Winterlight Labs has seen strong interest from pharmaceutical companies and other potential partners who view the technology as a major improvement over current methods of detection or screening. The company has gained support from the pan-Canadian AGE-WELL Network of Centres of Excellence (NCE), the Ontario Brain Institute, Ontario Centres of Excellence, and the University of Toronto Banting and Best Centre for Innovation and Entrepreneurship. For more information, visit www.winterlightlabs.com.
Liam Kaufman, CEO
liam [at] winterlightlabs.com